Standard BioTools Inc.
NASDAQ:LABMedical - Devices
+$0.03 today
- Market cap
- $225.03M
- Beta
- 1.38
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$0.24
Volume 0.70M
Average 2.91M
LAB Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Standard BioTools Inc.NASDAQ: LAB
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $570K (cash outflow) fell 88.7% year over year, behind the -69.8% change in trailing-twelve-month capital expenditures. Sequentially, it rose 19.7% from the prior quarter. Over 3 fiscal years it compounded at +29.5% a year.
Context
- Capital expenditures amounted to 9.7% of revenue in FY2025, up 4.9 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -88.7% toward the trailing-twelve-month pace of -69.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (8.3M) USD
- Year-over-year change
- +0.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.3M) | +0.6% |
| FY2024 | 2024-12-31 | (8.36M) | -195.1% |
| FY2023 | 2023-12-31 | (2.83M) | +26.0% |
| FY2022 | 2022-12-31 | (3.83M) | +71.2% |
| FY2021 | 2021-12-31 | (13.26M) | — |
Capital Expenditures vs competitors
How LAB compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -69.8% is the 8th highest of 9, against a peer median of +24.5%.
- Capital expenditures amounts to 4.4% of revenue for LAB, versus a peer median of 3.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | CN¥196.62M CNY | — | +132.2% | 13.0% | |
| LTM Mar 2026 | $29.2M USD | +43.1% | +17.9% | 4.1% | |
| LTM Apr 2026 | $28.8M USD | +32.7% | +2.4% | 3.4% | |
| LTM Mar 2026 | $13.04M USD | +16.3% | -3.1% | 6.3% | |
| LTM Mar 2026 | $8.64M USD | -28.2% | +3.5% | 3.6% | |
| LTM Mar 2026 | $5.4M USD | +43.5% | -25.5% | 2.6% | |
| LTM Mar 2026 | $3.82M USD | -69.8% | +29.5% | 4.4% | |
| LTM Mar 2026 | $2.31M USD | +49.9% | +20.1% | 0.4% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $744K USD | -50.0% | +14.1% | 0.8% |
| LTM Mar 2026 | $57.04K USD | -90.5% | -27.3% | 0.1% | |
| LTM Mar 2026 | $11K USD | — | -64.9% | — | |
| Peer median (excluding LAB) | — | +24.5% | +3.0% | 3.4% | |
Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (59.24M) | (190.1M) | (74.66M) | (138.89M) | (74.9M) |
| Depreciation & Amortization | 16.2M | 15.03M | 15.18M | 16.86M | 1.72M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.1M | 14.88M | 13.12M | 31.73M | 29.61M |
| Change in Working Capital | (18.01M) | (12.35M) | 1.79M | (12.08M) | (44.98M) |
| Accounts Receivables | 6.73M | 1.06M | (2.99M) | 8.97M | (1.36M) |
| Inventory | (4.78M) | (8.47M) | (4.91M) | (9.88M) | (11.52M) |
| Accounts Payables | 0 | 0 | 1.62M | 0 | 2.44M |
| Other Working Capital | (19.95M) | (4.95M) | 8.07M | (11.17M) | (34.53M) |
| Other Non-Cash Items | 886K | 83.17M | 1.28M | (41.08M) | 14.2M |
| Operating Cash Flow | (44.06M) | (89.37M) | (43.29M) | (143.45M) | (74.35M) |
| Capital Expenditures | (13.26M) | (3.83M) | (2.83M) | (8.36M) | (8.3M) |
| Acquisitions (Net) | 0 | 0 | 0 | 278.65M | 0 |
| Purchases of Investments | 0 | 0 | (94.9M) | 0 | (140.93M) |
| Sales of Investments | 0 | 0 | 117.96M | 0 | 179M |
| Other Investing Activities | 1.32M | (84.3M) | 0 | 92.88M | (5M) |
| Investing Cash Flow | (11.95M) | (88.13M) | 20.24M | 363.17M | 24.77M |
| Debt Repayment | 9.5M | 18.16M | (2.08M) | (63.19M) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 1.05M |
| Common Stock Repurchased | (1.79M) | (774K) | (5.41M) | (40.95M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.25M | 213.37M | 827K | 1.53M | (484K) |
| Financing Cash Flow | 15.96M | 230.76M | (6.81M) | (102.62M) | 570K |
| Effect of Forex Changes | (21K) | (404K) | 34K | (785K) | 842K |
| Net Change in Cash | (40.07M) | 52.86M | (29.83M) | 116.32M | (48.17M) |
| Free Cash Flow | (57.33M) | (93.2M) | (46.12M) | (151.81M) | (82.65M) |
Standard BioTools Inc.
NASDAQ:LAB
Intrinsic Alpha fair value
Locked
Current Price
$0.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.